Date of Award
Master of Science
Locally advanced breast cancer (LABC) is an aggressive form of pre- metastatic breast cancer, with an expected five-year survival rate of 30-42%. The current standard of treatment is neoadjuvant therapy; however there is a limited ability to monitor tumor response to this treatment. This study looks at two innovative approaches to monitoring tumor response: measurement of plasma osteopontin (OPN) levels and three dimensional ultrasound imaging (3D US). Using our laboratory’s in house ELISA, we found that 39% of LABC patients had plasma OPN levels elevated above the normal healthy range of I23ng/ml (Bramwell,20o6). Over treatment this percent increased, such that at final cycle, 63% patients had elevated OPN levels. Plasma OPN levels at the final two cycles of treatment were significantly different from early levels (p
Caria, Laura B.R., "Corrélation of Plasma Osteopontin Levels and 3D US Imaging with Tumor Response to Neoadjuvant Therapy" (2008). Digitized Theses. 4083.